Similar mechanisms of MC38 tumor control have been reported for anti-CD47 antibodies [33, 54], and for ALX148, a CD47 blocking Fc-fusion protein [13], suggesting that the antitumor effects of targeting SIRPα broadly recapitulate that of CD47-targeted therapies despite differences in the ligand expression patterns and molecular and cellular functions of SIRPα and CD47. This evidence concerns the gene CD47 and neoplasm.